In a study, anti-TNF-α antibodies (infliximab and etanercept) reduces HCC cell viability via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxic effects (Li and Jian, 2018). Here, TNF is linked to hepatocellular carcinoma.